Obesity is arguably the most pressing public health issue in the United States with its chronic progression that is associated with both type 2 diabetes and adverse cardiovascular health. Current therapies have struggled to achieve meaningful weight loss without compromising the overall risk-benefit of intervention. Following a series of high profile market withdrawals, the barren obesity drug landscape saw a relative rush of new treatment options come to market from 2012 to 2017. In this report, endocrinologists reveal how the current generation of antiobesity drugs compare with one another and what attributes the next generation of these agents will need to crack this medically important and potentially lucrative market.
- What are the treatment drivers and goals for obesity?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for obesity?
- What are the prevailing areas of unmet need and opportunity in obesity?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European endocrinologists for a hypothetical new obesity drug?
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European endocrinologists fielded in December 2018.
Key companies: Novo Nordisk, Eisai, Vivus, Orexigen Therapeutics, Pernix Therapeutics.
Key drugs: Saxenda, Qsymia, Contrave/Mysimba, Belviq.